Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Proceedings of the National Academy of Sciences of the United States of America|November 4, 2009
Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritisGraham P Wright, Clare A Notley, Shao-An Xue, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2009
Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr micePaul A Blair, Karina A Chavez-Rueda, Jamie G Evans, et al.
Clinical Rheumatology|January 25, 2012
Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: addressing treatment outside the current NICE guidanceYee Chiu, Andrew J K Ostor, Anthony Hammond, et al.
Rheumatology Advances in Practice|March 12, 2024
Differences in management approaches for lupus nephritis within the UKSara T Ibrahim, Christopher J Edwards, Michael R Ehrenstein, et al.
Frontiers in Immunology|May 19, 2018
Clinical Remission of Sight-Threatening Non-Infectious Uveitis Is Characterized by an Upregulation of Peripheral T-Regulatory Cell Polarized Towards T-bet and TIGITRose M Gilbert, Xiaozhe Zhang, Robert D Sampson, et al.
The Journal of Experimental Medicine|February 20, 2013
Germinal center B cells govern their own fate via antibody feedbackYang Zhang, Michael Meyer-Hermann, Laura A George, et al.
Nature Reviews. Rheumatology|January 25, 2018
Corrigendum: The RA-MAP Consortium: a working model for academia-industry collaborationAndrew P Cope, Michael R Barnes, Alexandra Belson, et al.
Nature Reviews. Rheumatology|December 8, 2017
The RA-MAP Consortium: a working model for academia-industry collaborationAndrew P Cope, Michael R Barnes, Alexandra Belson, et al.
The Lancet. Rheumatology|January 22, 2024
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trialsFelice Rivellese, Alessandra Nerviani, Giovanni Giorli, et al.
Pageof 7